Search form
Search
contact us
Navigation
home
boards
job ratings
cp wire
medtech news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» Shionogi
Shionogi
2023’s biggest launches: the story so far
2023’s biggest launches: the story so far
EP Vantage
drug launches
AbbVie
Almirall
Apellis Pharmaceuticals
Astellas
AstraZeneca
Biogen
CRISPR Therapeutics
Daiichi Sankyo
Eli Lilly
Genmab
GSK
Iveric Bio
Pfizer
Roche
SAGE Therapeutics
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Vertex Pharmaceuticals
Flag link:
Shionogi starts global Phase II clinical trial of redasemtide
Shionogi starts global Phase II clinical trial of redasemtide
Clinical Trials Arena
Shionogi
clinical trials
redasemtide
stroke
Flag link:
Shionogi's COVID-19 antiviral nabs Japanese approval to rival drugs from Pfizer, Merck
Shionogi's COVID-19 antiviral nabs Japanese approval to rival drugs from Pfizer, Merck
Fierce Pharma
Shionogi
COVID-19
antivirals
Japan
Flag link:
Shionogi's COVID-19 vaccine matches Pfizer's Comirnaty in booster trial
Shionogi's COVID-19 vaccine matches Pfizer's Comirnaty in booster trial
Fierce Biotech
Shionogi
vaccines
COVID-19
Japan
Pfizer
Flag link:
Shionogi files for approval of oral COVID-19 antiviral in Japan, brushing off missed clinical endpoint in race to market
Shionogi files for approval of oral COVID-19 antiviral in Japan, brushing off missed clinical endpoint in race to market
Fierce Biotech
Shionogi
Japan
antivirals
COVID-19
Flag link:
Shionogi licenses out 3rd-gen HIV asset to ViiV, notches a flop in chronic cough
Shionogi licenses out 3rd-gen HIV asset to ViiV, notches a flop in chronic cough
Fierce Biotech
Shionogi
HUV
ViiV Healthcare
clinical trials
chronic cough
sivopixant
Flag link:
One year after Fetroja approval, Shionogi expands label to include difficult-to-treat pneumonia
One year after Fetroja approval, Shionogi expands label to include difficult-to-treat pneumonia
Endpoints
Fetroja
Shionogi
hospital-acquired pneumonia
ventilator-associated bacterial pneumonia
FDA
Flag link:
Biopharma takeovers show quantity, if not quality
Biopharma takeovers show quantity, if not quality
EP Vantage
COVID-19
pandemic
M&A
Novo Nordisk
Corvidia
Gilead Sciences
Pionyr
Alexion
Portola Pharmaceuticals
Menarini
Stemline Therapeutics
Shionogi
Tetra Therapeutics
Flag link:
PhII Alzheimer's data looming, Shionogi spending up to $500M on a buyout involving one of the toughest bets in biotech
PhII Alzheimer's data looming, Shionogi spending up to $500M on a buyout involving one of the toughest bets in biotech
Endpoints
Shionogi
Alzheimer's disease
Tetra Therapeutics
M&A
Flag link:
Shionogi boosts Tetra Alzheimer's deal, nabs buyout option
Shionogi boosts Tetra Alzheimer's deal, nabs buyout option
Fierce Biotech
Shionogi
Tetra Therapeutics
R&D
M&A
Flag link:
Roche's Xofluza may give rise to resistant strains, raising fears of a 'worst case scenario'
Roche's Xofluza may give rise to resistant strains, raising fears of a 'worst case scenario'
Endpoints
Roche
Xofluza
Japan
Shionogi
Flu
influenza
Flag link:
After positive panel vote, Shionogi antibiotic scores US approval
After positive panel vote, Shionogi antibiotic scores US approval
Endpoints
Shionogi
antibiotics
FDA
cUTI
UTIs
Fetroja
Flag link:
Despite worries triggered by imbalance of deaths, Shionogi's antibiotic clears FDA panel vote
Despite worries triggered by imbalance of deaths, Shionogi's antibiotic clears FDA panel vote
Endpoints
Shionogi
FDA
advisory panels
antibiotics
cefiderocol
UTIs
Flag link:
In-house FDA review flags a suspicious imbalance in deaths as Shionogi hunts an OK for antibiotic
In-house FDA review flags a suspicious imbalance in deaths as Shionogi hunts an OK for antibiotic
Endpoints
Shionogi
FDA
advisory panels
antibiotics
UTIs
cefiderocol
Flag link:
Shionogi celebrates antibiotic win in pneumonia just ahead of its date with FDA regulators
Shionogi celebrates antibiotic win in pneumonia just ahead of its date with FDA regulators
Endpoints
Shionogi
antibiotics
FDA
cefiderocol
nosocomial pneumonia
Flag link:
Two years following US approval, Japan's Shionogi wins EU green light for opioid constipation drug
Two years following US approval, Japan's Shionogi wins EU green light for opioid constipation drug
Endpoints
Shionogi
Europe
opioid-induced constipation
Symproic
Rizmoic
Flag link:
FDA Approves First New Flu Drug in Nearly 20 Years
FDA Approves First New Flu Drug in Nearly 20 Years
CP Wire
FDA
Xofluza
Flu
Shionogi
Roche
Tamiflu
Flag link:
FDA Approves First New Flu Drug in Nearly 20 Years
Shionogi
Roche
Xofluza
Tamiflu
influenza
Flag link:
Fast-acting flu drug shows strong potential, but clinical trial results also raise concerns
Fast-acting flu drug shows strong potential, but clinical trial results also raise concerns
Stat
clinical trials
Flu
influenza
baloxavir marboxil
Xofluza
Shionogi
Flag link:
Shire, Shionogi File NDA for Intuniv for Adults in Japan
Shire, Shionogi File NDA for Intuniv for Adults in Japan
Yahoo/Zacks.com
Shire
Shionogi
ADHD
Japan
Intuniv
Flag link:
Pages
1
2
3
next ›
last »